China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the initiation of an investigator-initiated-trial (ITT) for its chimeric antigen receptor (CAR)-T therapy candidate product, KJ-C2219, in China. The trial is aimed at treating recurrent/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
KJ-C2219: A Universal CAR-T Therapy Targeting CD19 and CD20
KJ-C2219 is a universal CAR-T therapy that targets both CD19 and CD20, developed through CARsgen’s THANK-u Plus platform. This innovative platform enables continuous amplification and ensures a high level of anti-tumor efficacy, making KJ-C2219 a promising candidate for advanced cancer treatments.
Potential Applications in Hematological Malignancies and Autoimmune Diseases
KJ-C2219 is positioned to be developed for the treatment of not only hematological malignancies but also autoimmune diseases. The initiation of this ITT marks a significant step forward in the advancement of this therapy, which could potentially transform the treatment landscape for patients suffering from these conditions.-Fineline Info & Tech
